CD34 and mitochondrial neurogastrointestinal encephalomyopathy: In summary, this study has provided the first proof of principle demonstration of the enhancement of ex vivo-produced reticulocytes, from either CD34+ cells or an erythroid line, by engineering the cells during red cell development to overexpress TP as a novel cellular therapy treatment for MNGIE.